Genes explain GLP‑1 wins
A big genetics study used data from nearly 28,000 people to show that specific DNA variants help explain why GLP‑1 weight-loss drugs work much better for some people and also why some get gastrointestinal side effects ((nature.com), El-Balad). That matters because it moves obesity treatment toward personalization — in practice, doctors might one day use a patient’s genetic profile to predict benefit and side‑effect risk from GLP‑1s rather than relying on trial and error ((nature.com)).
These drugs copy a gut hormone your body already makes after you eat. That hormone tells the brain “you’ve had enough,” slows how fast food leaves the stomach, and pushes the pancreas to release insulin. (nature.com) The medicines work by pressing the same biological doorbell over and over. Semaglutide hits the glucagon-like peptide 1 receptor, and tirzepatide hits that receptor plus a second one called the gastric inhibitory polypeptide receptor. (nature.com) That is why two people can take the same shot and get very different results. In obesity treatment, some people lose less than 5% of body weight, while others lose more than 20%, and nausea or vomiting can range from none to severe. (mediacenter.23andme.com) The new study asked whether part of that difference is written into DNA before the first injection ever happens. Researchers ran a genome-wide association study, which is a sweep across the genome looking for tiny letter changes that show up more often in people with a shared outcome. (nature.com, blog.23andme.com) They used data from 27,885 people who reported their experiences on glucagon-like peptide 1 medicines. The team compared genetic variants with two real-world outcomes: weight lost and stomach side effects such as nausea or vomiting. (nature.com) One of the clearest hits landed in the glucagon-like peptide 1 receptor gene itself. People carrying a missense variant there — a one-letter DNA change that slightly alters the receptor protein — were expected to lose an extra 0.76 kilograms, or about 1.7 pounds, per copy of that variant. (nature.com, mediacenter.23andme.com) The side-effect signal pointed to the same pathway. Variants in the glucagon-like peptide 1 receptor gene and in the gastric inhibitory polypeptide receptor gene were linked to nausea or vomiting from treatment. (nature.com, nature.com) One detail makes the result more useful than a generic “genes matter” headline. The gastric inhibitory polypeptide receptor link to nausea showed up in people taking tirzepatide, which targets both receptors, and not in people taking semaglutide, which does not hit that second receptor. (nature.com, mediacenter.23andme.com) That gives researchers a cleaner explanation for why the same class of obesity drugs can feel different in the body. If the drug works by docking onto a receptor, then small inherited changes in the receptor can change how strong the effect feels, like two keys that fit the same lock slightly differently. (nature.com, nature.com) The team then folded those variants into a broader prediction model with clinical and demographic data. In the paper, that model could sort people by both likely weight-loss benefit and likely side-effect risk. (nature.com, mediacenter.23andme.com) It is not a crystal ball yet, because genes explain only part of the story and factors like dose, diet, exercise, and adherence still matter. But this is one of the first large studies to show, with nearly 28,000 people, that the biology of response sits in the drug-target genes themselves. (scientificamerican.com, nature.com) The practical next step is easy to picture. Instead of today’s trial-and-error approach, a doctor could eventually look at a patient’s genetic profile and ask two concrete questions before prescribing: how much weight loss is this person likely to get, and how likely are nausea and vomiting on this specific drug. (nature.com, mediacenter.23andme.com)
